Internal Market Committee seeks fine-tuning on several points

摘要

Two draft opinions on the pharmaceu-ticals package were debated, on 26 January, by the European Parliament's Committee on Internal Market (IMCO)'. They are set for adoption in February. According to MEPs, certain points of the European Commission's proposals on drug monitoring and on combating counterfeit drugs need to be fine-tuned.rnOn the update of drug monitoring rules2, Philippe Juvin (EPP, France) observed that the existing system does not work well, primarily due to a tendency to under-declare the undesirable side effects of drugs. For rapporteur Claude Turmes (Greens-EFA, Luxembourg), it is useful for patients to be able to participate in identifying unwanted effects, but they are not experts. It is therefore necessary to put in place a system based on regional and national centres to filter information provided by patients.